netFormulary NHS
Shropshire and Telford Local Health Economy
Shropshire, Telford and Wrekin CCG
Shrewsbury and Telford Hospitals NHS Trust
Robert Jones & Agnes Hunt Orthopaedic Hospital NHS Foundation Trust
Shropshire Community Health NHS Trust
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
08.01.05  Expand sub section  Other antineoplastic drugs
Durvalumab (Imfinzi ®)
(50mg/ml)
View adult BNF View SPC online View childrens BNF
Formulary
Red
Cancer Drugs Fund
NHS England
BlueTeq

This drug is funded by the CDF for the indication outlined within the CDF list (Blueteq Drug)

 
Link  NICE TA578: Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation
   
Cytotoxic Drug Abemaciclib (Verzenios ®)
(50mg)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
BlueTeq

This drug is NHSE funded for the indications outlined within the Ex-Tariff List (Blueteq Drug) 

This drug is funded by the CDF for the indication outlined within the CDF list (Blueteq Drug)

 
Link  NICE TA563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Link  NICE TA579: Abemaciclib with fulvertrant for treating hormone receptor- positive, HER2-negative advanced breast cancer after endocrine therapy
   
Acalabrutinib
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq

This drug is funded by the CDF for the indication outlined within the CDF list (Blueteq Drug)

 
   
Cytotoxic Drug Alectinib (Alecensa®)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

This drug is NHSE funded for the indications outlined within the Ex-Tariff List (Blueteq Drug)

Suitable for shared care between specialist and secondary care via network model.

 
Link  TA536 - Alectinib for untreated ALK-positive advanced non-small-cell lung cancer
   
Atezolizumab (Tecentriq®)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
BlueTeq

This drug is NHSE funded for the indications outlined within the Ex-Tariff list (Blueteq Drug)

This drug is funded by the CDF for the indication outlined within the CDF list (Blueteq Drug)

Suitable for shared care between specialist and secondary care via network model.

 
Link  NICE TA492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Link  NICE TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
Link  NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Link  NICE TA584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer
Link  NICE TA638: Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer
Link  NICE TA639: Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer
Link  NICE TA666: Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma
Link  NICE TA705: Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer
   
Avelumab (Bavencio)
(20mg/ml)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
BlueTeq

This drug is NHSE funded for the indication outlined within the Ex-Tariff list (Blueteq Drug).

This drug is funded by the CDF for the indication outlined within the CDF list (Blueteq Drug)

Suitable for shared care between specialist and secondary care via network model.

 
Link  NICE TA517: Avelumab for treating metastatic Merkel cell carcinoma
Link  NICE TA645: Avelumab with axitinib for untreated advanced renal cell carcinoma
Link  NICE TA691: Avelumab for untreated metastatic Merkel cell carcinoma
   
Cytotoxic Drug Axitinib (Inlyta®)
(1mg
5mg
7mg)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
NHS England

This drug is NHSE funded for the indication outlined within the Ex-Tariff list (Blueteq Drug).

Suitable for shared care between specialist and secondary care via network model.

 
Link  NICE TA333: Axitinib for advanced renal cell carcinoma
   
Cytotoxic Drug Bosutinib (Bosulif®)
(100mg
500mg)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

This drug is NHSE funded for the indication outlined within the Ex-Tariff list (Blueteq Drug).

Suitable for shared care between specialist and secondary care via network model.

 
Link  NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia
   
Cytotoxic Drug Brigatinib (Alunbrig)
(30mg,
90mg,
180mg)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

This drug is NHSE funded for the indication outlined within the Ex-Tariff list (Blueteq Drug).

Suitable for shared care between specialist and secondary care via network model.

 
Link  NICE TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
Link  NICE TA670: Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor
   
Cytotoxic Drug Cabozantinib (Cabometyx® Cometriq®)
(20mg
80mg)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Ths drug is NHSE funded for the indication outlined within the Ex-Tariff list (Blueteq Drug).

Suitable for shared care between specialist and secondary care via network model.

 
Link  NICE TA463: Cabozantinib for previously treated advanced renal cell carcinoma in adults
Link  NICE TA516: Cabozantinib for treating medullary thyroid cancer
Link  NICE TA542: Cabozantinib for untreates advanced renal cell carcinoma
   
Cytotoxic Drug Carfilzomib (Kyprolis®)
(2mg/ml)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
BlueTeq

This drug is NHSE funded for the indication outlined within the Ex-Tariff list (Blueteq Drug).

This drug is funded by the CDF for the indication outlined within the CDF list. (Blueteq Drug)

Suitable for shared care between specialist and secondary care via network model.

 
Link  NICE TA695: Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma
Link  TA657: Carfilzomib for previously treated multiple myeloma
   
Cytotoxic Drug Ceritinib (Zykadia®)
(150mg)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

This drug is NHSE funded for the indication outlined within the Ex-Tariff list (Blueteq Drug)

Suitable for shared care between specialist and secondary care via network model.

 
Link  NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
Link  NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
   
Cytotoxic Drug Dabrafenib (Tafinlar®)
(50mg)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

This drug is NHSE funded for the indication outlined within the Ex-Tariff list.

This drug is funded by the CDF for the indication outlined within the CDF list.

 
Link  NICE TA321:Dabrafenib for BRAF V600 +ve melanoma
Link  NICE TA396:Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Link  NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
   
Cytotoxic Drug Dacomitinib (Vizimpro ®)
(15mg, 30mg, 45mg)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

This drug is NHSE funded for the indications outlined within the NICE guidance (Blueteq Drug)

Suitable for shared care between specialist and secondary care via network model.

 
Link  NICE TA595: Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer
   
Daratumumab (Darzalex®)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
BlueTeq

This drug is CDF funded for the indications outlined within the NICE guidance (Blueteq Drug)

Suitable for shared care between specialist and secondary care via network model.

 
Link  NICE TA510:Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
Link  NICE TA573:Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
   
Dupilumab
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
CCG
Homecare
BlueTeq

 

 
Link  NICE TA534: Dupilumab for treating moderate to severe atopic dermatitis
   
Cytotoxic Drug Encorafenib (Braftovi®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

This drug is NHSE funded for the indications outlined within the Ex-Tariff List (Blueteq Drug) 

Suitable for shared care between specialist and secondary care via network model

 
Link  NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
Link  NICE TA668: Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer
   
Entrectinib
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
BlueTeq

This drug is NHSE funded for the indications outlined within the Ex-Tariff list (Blueteq drug)

This drug is funded by the CDF for the indications outlined within the CDF list (Blueteq Drug).

Suitable for shared care between specialist and secondary care via network model.

 
Link  NICE TA643: Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer
Link  NICE TA644: Entrectinib for treating NTRK fusion-positive solid tumours
   
Cytotoxic Drug Eribulin (Halaven®)
(440mcg/ml)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

This drug is NHSE funded for the indication outlined within the Ex-Tariff list (Blueteq Drug)

Suitable for shared care between specialist and secondary care via network model.

 
Link  NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
   
Cytotoxic Drug GilteritinibBlack Triangle
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

This drug is NHSE funded for the indications outlined within the Ex-Tariff list.

Suitable for shared care between specialist and secondary care via network model.

 
Link  NICE TA642: Gilteritinib for treating relapsed or refractory acute myeloid leukaemia
   
Ibrutinib (Imbruvica®)
(140mg)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
BlueTeq

This drug is NHSE funded for the indications outlined within the Ex-Tariff list (Blueteq drug)

This drug is funded by the CDF for the indications outlined within the CDF list (Blueteq Drug).

Suitable for shared care between specialist and secondary care via network model.

 
Link  NICE TA429 : Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
Link  NICE TA491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia
Link  NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
   
Idelalisib (Zydelig®)
(100mg
150mg)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
NHS England

This drug is NHSE funded for the indications outlined within the Ex-Tariff list.

Suitable for shared care between specialist and secondary care via network model.

 
Link  NICE TA359: Chronic lymphocytic leukaemia - Idelalisib
   
Cytotoxic Drug Irinotecan hydrochloride trihydrate  (Onivyde®)
(5mg/ml
20mg/ml)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
NHS England

NHSE funded as part of routine commissioning for chemotherapy regimes

 
   
Ixazomib (Ninlaro®)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq

This drug is commissioned for the indication outlined within the Ex-Tariff list with an IFR approval requirement for specialist centres.

This drug is funded by the CDF for the indication outlined within the CDF list (Blueteq Drug)

 Suitable for shared care between specialist and secondary care via network model.

 
Link  NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
   
Larotrectinib (Vitrakvi)
(20mg/ml)
View adult BNF View SPC online View childrens BNF
Formulary
Red
Cancer Drugs Fund
BlueTeq

This drug is funded by the CDF for the indication outlined within the CDF list (Blueteq Drug)

 
Link  NICE TA630: Larotrectinib for treating NTRK fusion-positive solid tumours
   
Lenvatinib (Lenvima®)
View adult BNF View SPC online
Formulary
Amber
High Cost Medicine
NHS England
BlueTeq

This drug is NHSE funded for the indications outlined within the Ex-Tariff list (Blueteq Drug).

Suitable for shared care between specialist and secondary care via network model.

 
   
Neratinib (Nerlynx ®)
(40mg)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

This drug is NHSE funded for the indications outlined within the NICE guidance (Blueteq Drug)

Suitable for shared care between specialist and secondary care via network model.

 
Link  NICE TA612: Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab
   
Cytotoxic Drug Panitumumab (Vectibix®)
(20mg/ml)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

This drug is NHSE funded for the indications outlined within the Ex-Tariff list (Blueteq Drug).

Suitable for shared care between specialist and secondary care via network model.

 
Link  NICE TA439 : Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
   
Cytotoxic Drug Panobinostat (Farydak®)
(10mg
15mg
20mg)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
NHS England

This drug is NHSE funded for the indications outlined within the Ex-Tariff list.

 
Link  NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
   
Pembrolizumab (Keytruda®)
(50mg)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
BlueTeq

This drug is NHSE funded for the indication outlined within the Ex-Tariff list (Blueteq Drug)

This drug is funded by the CDF for the indication outlined within the CDF list (Blueteq Drug)

Suitable for shared care between specialist and secondary care via network model.

Please note that Pembrolizumab for drug-resistant gestational trophoblastic neoplasia (170027P) is for specialist centre use only. As according to commissioning policy 170027P

 
Link  In development [GID-TA10420]: Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency ID1498
Link  NICE TA357: Pembrolizumab for melanoma after ipilimumab
Link  NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab
Link  NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
Link  NICE TA531:-Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
Link  NICE TA540: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma
Link  NICE TA553: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence
Link  NICE TA600: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer
Link  NICE TA661: Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma
Link  NICE TA683: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
Link  NICE TA692: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
   
Polatuzumab vedotin (Polivy®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

This drug is NHSE funded for the indications outlined within the Ex-Tariff list (Blueteq Drug).

Suitable for shared care between specialist and secondary care via network model

 
Link  NICE TA649:Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma
   
Cytotoxic Drug Ponatinib (Iclusig®)
(15mg
45mg)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

This drug is NHSE funded for the indications outlined within the Ex-Tariff list (Blueteq Drug)

Suitable for shared care between specialist and secondary care via network model.

 
Link  NICE TA451 : Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
   
Ramucirumab (Cyramza®)
(10mg/ml)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
NHS England

This drug is NHSE funded for the indication outlined in the Ex-Tariff list at specialised centres only.

An IFR is needed if using outdside of commisoning policy.

 
Link  NICE TA403: Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer
   
Ribociclib (Kisqali®)
(200mg)
View adult BNF View SPC online View childrens BNF
Formulary
Red
Cancer Drugs Fund
NHS England
BlueTeq

Ths drug is NHSE funded for the indication outlined within the Ex-Tariff list (Blueteq Drug).

This drug is funded by the CDF for the indication outlined within theCDF list (Blueteq Drug)

Suitable for shared care between specialist and secondary care via network model.

 
Link  NICE TA496: Ribociclib with an aromastase inhibitor for previously untreated, hormone receptor- positive, HER2-negative, locally advanced or metastatic breast cancer
Link  NICE TA687: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
   
Cytotoxic Drug Rucaparib (Rubraca ® )
(200mg, 250mg, 300mg)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
BlueTeq

This drug is CDF funded for the indications outlined within the Ex-Tariff list (Blueteq Drug)

Suitable for shared care between specialist and secondary care via network model.

 
Link  NICE TA611: Rucaparib for maintenance tretment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
   
Cytotoxic Drug Ruxolitinib (Jakavi®)
(5mg
15mg
20mg)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

This drug is NHSE funded for the indication outlined within the Ex-Tariff list.

Suitable for shared care between specialist and secondary care via network model.

 
Link  NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
   
Cytotoxic Drug Talimogene laherparepvec (Imlygic®)
(10x6 plaque froming units
10x8 plaque forming units)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

This drugs is NHSE funded for the indication oulined within the Ex-Tariff list (Blueteq Drug).

 
Link  NICE TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma
   
Trametinib (Mekinist®)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

This drugs is NHSE funded for the indication oulined within the Ex-Tariff list (Blueteq Drug).

Suitable for shared care between specialist and secondary care via network model.

 
Link  NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Link  NICE TA544:-Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
   
Cytotoxic Drug Trifluridine-tipiracil (Lonsurf®)
(15mg
20mg)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

This drug is NHSE funded for the indication outlined within the Ex-Tariff list (Blueteq Drug).

Suitable for shared care between specialist and secondary care via network model.

 
Link  NICE TA405: Trifluridine-tipiracil for previously treated metastatic colorecal cancer
   
Venetoclax (Venclyxto®)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
BlueTeq

Ths drug is NHSE funded for the indication outlined within the Ex-Tariff list (Blueteq Drug).

This drug is funded by the CDF for the indication outlined within the CDF list (Blueteq Drug)

Suitable for shared care between specialist and secondary care via network model.

 
Link  NICE TA487: Venetoclax for treating chronic lymphocytic leukaemia
Link  NICE TA663: Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia
   
08.01.05  Expand sub section  Arsenic trioxide
Cytotoxic Drug Arsenic Trioxide (Trisenox®)
(1mg/ml)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
NHS England

This drug is NHSE funded for the indication outlined within the Ex-Tariff list (Blueteq Drug).

Suitable for shared care between specialist and secondary care via network model.

 
Link  NICE TA526: Arsenic trioxide for treating acute promyelocytic leukaemia
   
08.01.05  Expand sub section  Bevacizumab
Bevacizumab (Avastin®)
(25mg/ml)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

This drug is funded by the CDF for the indications outlined within the CDF list.

Suitable for shared care between specialist and secondary care via network model.

 
Link  NICE TA214: Breast Cancer with taxane
Link  NICE TA263: Breast cancer with capecitabine
Link  NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab
   
08.01.05  Expand sub section  Bortezomib
Cytotoxic Drug Bortezomib (Velcade®)
(3.5mg)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

This drug is funded by the CDF for the indications outlined within the CDF list.

Suitable for shared care between specialist and secondary care via network model.

 
Link  NICE TA:573 Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
Link  NICE TA129: Multiple myeloma - bortezomib
Link  NICE TA228: 1st line treatment of multiple myeloma
Link  NICE TA311: Bortezomib for induction therapy in multiple myeloma
Link  NICE TA370: Bortezomib for previously untreated mantle cell lymphoma
   
08.01.05  Expand sub section  Brentuximab vedotin to top
Brentuximab vedotin (Adcetris®)
(50mg)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

This drug is NHSE funded for the indications outlined within the Ex-Tariff list (Blueteq Drug)

Suitable for shared care between specialist and secondary care via network model.

 
Link  NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
Link  NICE TA524:-Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
Link  NICE TA577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma
Link  NICE TA641: Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma
   
08.01.05  Expand sub section  Cetuximab
Cetuximab (Erbitux®)
(5mg/ml)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

This drug is NHSE funded for the indications outlined within the Ex-Tariff list (Blueteq Drug)

 
Link  NICE TA145: Head and neck cancer - cetuximab
Link  NICE TA439 : Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Link  NICE TA473: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck
   
08.01.05  Expand sub section  Crisantaspase
Cytotoxic Drug Crisantaspase (Erwinase®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England

NHSE funded through routine commissioning for chemotherapy regimes

 
   
08.01.05  Expand sub section  Dacarbazine and Temozolomide
Cytotoxic Drug Dacarbazine
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England

NHSE funded through routine commissioning for chemotherapy regimes

 
   
Cytotoxic Drug Temozolomide (Temodal®)
(5mg
20mg
100mg
140mg
180mg
250mg)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England

This drug is NHSE funded for the indication outlined within the Ex-Tariff list 

 
Link  NICE TA121: Glioma (newly diagnosed and high grade)
Link  NICE TA23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)
   
08.01.05  Expand sub section  Erlotinib
Cytotoxic Drug Erlotinib (Tarceva® )
(25mg
100mg
150mg)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
NHS England

This drug is NHSE funded for the indication outlined within the Ex-Tariff list.

 
Link  NICE TA227: Lung cancer (non-small-cell) maintenance - erlotinib
Link  NICE TA258: Lung cancer (non-small-cell) 1st line- erlotinib
Link  NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
   
08.01.05  Expand sub section  Hydroxycarbamide to top
Cytotoxic Drug Hydroxycarbamide (Hydrea®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
   
08.01.05  Expand sub section  Ipilimumab
Ipilimumab (Yervoy®)
(5mg/ml)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England

This drug is NHSE funded for the indication outlined within the Ex-Tariff list.

 
Link  NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
Link  NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
Link  NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
   
08.01.05  Expand sub section  Pentostatin
Cytotoxic Drug Pentostatin (Nipent®)
(10mg)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
NHS England
 
   
08.01.05  Expand sub section  Platinum compounds
Cytotoxic Drug Carboplatin
(10mg/ml)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England

NHSE funded through routine commissioning for chemotherapy regimes

 
   
Cytotoxic Drug Carboplatin (Paraplatin®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England

NHSE funded through routine commissioning for chemotherapy regimes

 
   
Cytotoxic Drug Cisplatin
(1mg/ml
50mg)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England

NHSE funded through routine commissioning for chemotherapy regimes

 
   
Cytotoxic Drug Oxaliplatin
(50mg
5mg/ml)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
NHS England

NHSE funded through routine commissioning for chemotherapy regimes

 
Link  NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
   
08.01.05  Expand sub section  Procarbazine
Cytotoxic Drug Procarbazine
(50mg)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England

NHSE funded through routine commissioning for chemotherapy regimes

 
   
08.01.05  Expand sub section  Protein kinase inhibitors to top
Cytotoxic Drug Afatinib (Giotrif®)
(20mg
30mg
40mg
50mg)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
NHS England

This drug is NHSE funded for the indication outlined within the Ex-Tariff list.

Suitable for shared care between Specialist and Secondary Care via network model.

 
Link  NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
   
Cytotoxic Drug Binimetinib (Mektovi®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England

This drug is NHSE funded for the indications outlined within the Ex-Tariff List (Blueteq Drug)

 

 
Link  NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
   
Cytotoxic Drug Cabozantinib (Cometriq®)
(20mg
80mg)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

This drug is NHSE funded for the indication outlined within the Ex-Tariff list (Blueteq Drug).

This drug is funded by the CDF for the indication outlined wihin the CDF list  (Blueteq Drug)

 
Link  NICE TA463 : Cabozantinib for previously treated advanced renal cell carcinoma
Link  NICE TA516: Cabozantinib for treating medullary thyroid cancer
Link  NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma
   
Cytotoxic Drug Crizotinib (Xalkori®)
(200mg
250mg)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
BlueTeq

This drug is NHSE funded for the indications outlined within the Ex-Tariff list (Blueteq Drug)

 
Link  NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Link  NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cance
Link  NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
   
Cytotoxic Drug Dasatinib (Sprycel®)
(20mg
50mg
80
100mg
140mg
)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

This drug is NHSE funded for the indication outlined within the Ex-Tariff list (Blueteq Drug)

 
Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
   
Cytotoxic Drug Everolimus (Afinitor®)
(5mg
10mg)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

This drug is NHSE funded for the indication outlined within the Ex-Tariff list (Blueteq Drug)

 
Link  NICE TA348: Preventing Rejection in Liver Transplant
Link  NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
Link  NICE TA449 : Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Link  NICE TA498:Lenvatinib with everolimus for previously treaed advanced renal cell carcinoma
   
Cytotoxic Drug Everolimus (Votubia®)
(2.5mg
5mg
10mg)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

This drug is NHSE funded for the indication outlined within the policy

 

 
   
Cytotoxic Drug Gefitinib (Iressa®)
(250mg)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
NHS England

This drug is NHSE funded for tthe indication outlined within the Ex-Tariff list.

 
Link  NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib
Link  NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
   
Cytotoxic Drug Imatinib (Gilvec®)
(100mg
500mg
)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England

This drug is NHSE funded for the indication outlined within the Ex-Tariff list.

 
Link  NICE TA209: Imatinib for the treatment of unresectable and/or metastatic gastrointestinal tumours
Link  NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
Link  NICE TA70: Imatinib for CML
Link  NICE TA86: Imatinib for the treatment of unresectable and/or metastatic gastrointestinal tumours
   
Cytotoxic Drug Lorlatinib
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
Homecare
BlueTeq

This drug is NHSE funded for the indications outlined within the Ex-Tariff list (Blueteq Drug)

 

 
Link  NICE TA628: Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer
   
Cytotoxic Drug Nilotinib (Tasigna®)
(150mg
200mg)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

This drug is NHSE funded for the indications outlined within the Ex-Tariff list (Blueteq Drug)

 

 
Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
   
Cytotoxic Drug Pazopanib (Votrient®)
(200mg
400mg)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
NHS England

This drug is NHSE funded for the indications outlined within the Ex-Tariff list.

 
Link  NICE TA215: Pazopanib in renal cell cancer
   
Cytotoxic Drug Regorafenib (Stivarga® )
(40mg)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
NHS England

This is NHSE funded for the indications outlined within the Ex-Tariff list.

 
Link  NICE TA488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
Link  NICE TA555: Regorafenib for previously treated advanced helpatocellular carcinoma
   
Cytotoxic Drug Sorafenib (Nexavar®)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

This drug is NHSE funded for the indication outlined within the Ex-Tariff list (Blueteq Drug).

 

This drug is funded by the CDF for the indication outlined within the CDF list.

 
Link  NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma
Link  NICE TA535: Lenvatininb and sorafenib for treating differentiated thyroid cancer after radioactive iodine
   
Cytotoxic Drug Sunitinib (Sutent®)
(12.5mg
25mg
50mg)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

This drug is NHSE funded for the indications outlined within the Ex-Tariff list (Blueteq Drug).

 
Link  NICE TA169: Renal cell carcinoma - sunitinib
Link  NICE TA179: Gastrointestinal stromal tumours - sunitinib
Link  NICE TA449 : Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
   
Cytotoxic Drug Vandetanib (Caprelsa®)
(100mg
300mg)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
NHS England

This drug is funded by NHSE for the indications outlined in the Ex-Tariff List. If the indciation for use lies outside this guideline an IFR is required.

 
Link  NICE TA550: Vandetanib for treating medullary thyroid cancer
   
Cytotoxic Drug Vemurafenib (Zelboraf®)
(240mg)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
NHS England

This drug is NHSE funded for the indications outlined within the Ex-Tariff list.

 
Link  NICE TA269: Vemurafenib for treating malignant melanoma
   
08.01.05  Expand sub section  Taxanes
Cytotoxic Drug Cabazitaxel (Jevtana®)
(40mg/ml)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

This drug is NHSE funded for the indications outlined within the Ex-Tariff list (Blueteq Drug)

 
Link  NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
   
Cytotoxic Drug Docetaxel (Taxotere®)
(10mg/ml
20mg/ml)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
NHS England
 
Link  NICE NG101:-Early and locally advanced breast cancer: diagnosis and management
Link  NICE TA101: Prostate cancer (hormone-refractory) - docetaxel
   
Cytotoxic Drug Paclitaxel
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

This drug is NHSE funded for the indication outlined within the Ex-Tariff list (Blueteq Drug)

 
Link  NICE NG101:-Early and locally advanced breast cancer: diagnosis and management
Link  NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Link  NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
   
08.01.05  Expand sub section  Topoisomerase I inhibitors
Cytotoxic Drug Irinotecan Hydrochloride
(20mg/ml)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
NHS England

NHSE funded through routine commissioning for chemotherapy regimes

 
Link  NICE TA440: Pegylated liposomal irinotecan for treating pancreatic cancer after gembcitabine
   
Cytotoxic Drug Topotecan (Hycamtin®)
(1mg/ml)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
NHS England

NHSE funded through routine commissioning for chemotherapy regimes

 
Link  NICE TA183: Cervical cancer (recurrent) - topotecan
Link  NICE TA184: Lung cancer (small-cell) - topotecan
Link  NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
   
08.01.05  Expand sub section  Trabectedin
Cytotoxic Drug Trabectedin (Yondelis®)
(1mg/ml)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
NHS England

This drug is NHSE funded for the indication outlined within the Ex-Tariff list.

 
Link  NICE TA 185:- Trabectidin for the treatment of advanced soft tissue sarcoma
Link  NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
   
08.01.05  Expand sub section  Trastuzumab
Cytotoxic Drug Pertuzumab (Perjeta®)
(30mg/ml)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

This drug is NHSE funded for the indications outlined within the Ex-Tariff list (Blueteq Drug)

This drug is funded by the CDF for the indications oulined within the CDF list (Blueteq Drug)

Suitable for shared care between specialist and secondary care via network model

 
Link  NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
Link  NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
Link  NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer
   
Cytotoxic Drug Trastuzumab (Herceptin®)
(120mg/ml)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
NHS England

This drug is NHSE funded for the indications outlined  within the Ex-Tariff list.

 
Link  NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab
Link  NICE TA257: Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2
Link  NICE TA34: Breast cancer - trastuzumab
   
Trastuzumab deruxtecanBlack Triangle (Enhertu®)
(20mg/ml - comes as powder for reconstitution)
View adult BNF View SPC online View SMC online
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq

Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens.

This drug is funded by the CDF for the indications oulined within the CDF list (Blueteq Drug)

 
Link  NICE TA704: Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies
   
Cytotoxic Drug Trastuzumab emtansine (Kadcyla®)
(100mg
160mg)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

This drug is NHSE funded for the indications outlined within the Ex-Tariff list (Blueteq Drug)

Suitable for shared care between specialist and secondary care via network model

 
Link  NICE TA458 : Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxan
Link  NICE TA632: Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer
   
08.01.05  Expand sub section  Tretinoin to top
Cytotoxic Drug Tretinoin (Vesanoid®)
(10mg)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England

NHSE funded through routine commissioning for chemotherapy regimes

 
   
08.01.05  Expand sub section  Vismodegib
 ....
 Non Formulary Items
Cytotoxic Drug  Aflibercept  (Zaltrap®)

View adult BNF View SPC online
Non Formulary
Black
High Cost Medicine

Aflibercept is funded by the NHSE only if an Individual Funding Request (IFR) has been approved.

TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy is not recommended within its marketing authorisation for treating metastatic colorectal cancer that is resistant to or has progressed after an oxaliplatin-containing regimen.

Link  NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
 
Elotuzumab  (Empliciti®)

View adult BNF View SPC online
Non Formulary
Black
Link  NICE TA434:-Elotuzumab for previously treated multiple myeloma (terminated appraisal)
 
Erlotinib  (Tarceva ®)
(25mg,
100mg,
150mg)

View adult BNF View SPC online View childrens BNF
Non Formulary
Red
High Cost Medicine
NHS England

This drug is NHSE funded for the indications outlined within the NICE guidance (Blueteq Drug)

 
Cytotoxic Drug  Erlotinib  (Tarceva®)
(25mg
100mg
150mg)

View adult BNF View SPC online
Non Formulary
Red
High Cost Medicine
NHS England

This drug is NHSE funded for the indication outlined within the Ex-Tariff list.

 
Glasdegib

View adult BNF View SPC online View childrens BNF
Non Formulary
Black

NICE is unable to make a recommendation about the use in the NHS of glasdegib with chemotherapy for untreated acute myeloid leukaemia because Pfizer did not provide an evidence submission. The company has confirmed that it does not intend to make a submission for the appraisal because the technology is unlikely to be a cost-effective use of NHS resources.

Link  NICE TA646: Glasdegib with chemotherapy for untreated acute myeloid leukaemia (terminated appraisal)
 
Cytotoxic Drug  Lapatinib  (Tyverb®)
(250mg)

View adult BNF View SPC online
Non Formulary
Black
High Cost Medicine

This drug is  funded by the NHSE only if an Individual Funding Request (IFR) has been approved.

Link  NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
 
Necitumumab  (Portrazza®)

View adult BNF View SPC online
Non Formulary
Black
High Cost Medicine
Link  NICE TA411: Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer
 
Cytotoxic Drug  Temsirolimus  (Torisel®)

View adult BNF View SPC online
Non Formulary
Black
High Cost Medicine
Cancer Drugs Fund
NHS England

This drug is  funded by the NHSE only if an Individual Funding Request (IFR) has been approved.

Link  NICE TA178:-Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
Link  NICE TA207:-Temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma (terminated appraisal)
 
Cytotoxic Drug  Vismodegib  (Erivedge®)

View adult BNF View SPC online
Non Formulary
Black
High Cost Medicine

Vismodegib is not recommended within its marketing authorisation for treating symptomatic metastatic basal cell carcinoma, or locally advanced basal cell carcinoma that is inappropriate for surgery or radiotherapy, in adults.

Link  NICE TA489: Vismodegib for treating basal cell carcinoma
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Green

Suitable first-line drugs for implementation in Primary Care  

Amber

These medicines are considered suitable for prescribing in Primary Care following specialist (consultant or GPwSI) initiation or recommendation. Some of these medicines may require on-going communication between the Secondary Care specialist and the Primary Care prescriber using Prescribing Information (PI) or through the use of an Effective Shared Care Agreement (ESCA) and this will be indicated in the text.  

Red

Drugs which require special consideration. These are drugs for use in Secondary Care ONLY, Consultant Prescribing ONLY or by Tertiary Centres ONLY where indicated in the text. They should not be prescribed in Primary Care.  

Black

Medicines classified in the BNF as 'not NHS' or are considered by the Area Prescribing Committee to be of low clinical value should not be prescribed  

netFormulary